Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06043427 | Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma | PHASE2 | RECRUITING | 168 | — | — | Apr 16, 2024 | Dec 31, 2026 | Jan 30, 2026 | 18 | Canada |
| Arm | Type | Description |
|---|---|---|
| Paclitaxel and Ramucriumab | ACTIVE_COMPARATOR | - |
| Zanidatamab + Paclitaxel and Ramucirumab | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Paclitaxel | DRUG | 80 mg/m² |
| Ramucirumab | DRUG | 8 mg/kg |
| Zanidatamab | DRUG | Dose and schedule to be assigned at enrollment |
Inclusion Criteria: * Participants must have histologically or pathologically confirmed gastroesophageal adenocarcinoma (stomach, gastroesophageal junction or esophagus) that is unresectable or metastatic and which must be HER2 positive as confirmed by central testing using FDA-approved HER2 assay....